Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | NPY4R | P50391 | 3/20 | 0.31 |
| ▸ | NPY1R | P25929 | 2/20 | 0.31 |
| ▸ | NPY2R | P49146 | 2/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.31 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | OTC | P00480 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.31 |
| ▸ | TUBB | P07437 | 1/20 | 0.31 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.31 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.31 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.31 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.31 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.31 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.31 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL15525634 | 0.94 | GSR (0.41) | GSRMMP2NPY4RNPY1RNPY2R | |
| Arginine SCHEMBL29263954 | 0.93 | GSR (0.42) | GSRMMP2NPY4RNPY1RNPY2R | |
| Arginine SCHEMBL28491547 | 0.93 | GSR (0.42) | GSRMMP2NPY4RNPY1RNPY2R | |
| Arginine SCHEMBL1063567 | 0.93 | GSR (0.42) | GSRMMP2NPY4RNPY1RNPY2R | |
| Arginine SCHEMBL693611 | 0.93 | GSR (0.42) | GSRMMP2NPY4RNPY1RNPY2R | |
| Arginine SCHEMBL14764665 | 0.93 | GSR (0.42) | GSRMMP2NPY4RNPY1RNPY2R | |
| Arginine SCHEMBL2337389 | 0.90 | GSR (0.39) | GSRMMP2NPY4RNPY1RNPY2R | |
| Arginine SCHEMBL20918548 | 0.90 | GSR (0.39) | GSRMMP2NPY4RNPY1RNPY2R | |
| Arginine SCHEMBL25294109 | 0.89 | GSR (0.38) | GSRMMP2NPY4RNPY1RNPY2R | |
| Arginine SCHEMBL8314691 | 0.89 | GSR (0.38) | GSRMMP2NPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247398-B2 | free of external ions; e.g. zinc bisarginate; copper-related conditions such as Wilson's disease, inflammatory disease, and/or a fibrotic disease; inducing metallothionein | SSV THERAPEUTICS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20080200443-A1 | Zinc complexes of natural amino acids for treating elevated copper caused toxicities | SSV THERAPEUTICS, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| WO-2008100418-A1 | ZINC COMPLEXES OF NATURAL AMINO ACIDS FOR TREATING ELEVATED COPPER CAUSED TOXICITIES | SSV THERAPEUTICS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200443-A1 | Zinc complexes of natural amino acids for treating elevated copper caused toxicities | SLC30A6, ARG1, OAT | GSR 1073/4885MMP2 3681/4885NPY4R 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.